Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.

about

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3.

P2860

Q37317385-58696FD6-3166-43A4-98E5-DA8A220632C6 Q53687540-B097FA70-340A-47F4-A9D5-3B325ACF6F60

P2860

Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.

Item

http://www.wikidata.org/entity/Q38658649

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Current and emerging triplet c ...... d refractory multiple myeloma.

@en

type

Item

label

Current and emerging triplet c ...... d refractory multiple myeloma.

@en

prefLabel

Current and emerging triplet c ...... d refractory multiple myeloma.

@en

P1476

Current and emerging triplet c ...... nd refractory multiple myeloma

@en

P2093

B A Zannetti

http://www.w3.org/2001/XMLSchema#string

C Terragna

http://www.w3.org/2001/XMLSchema#string

E Zamagni

http://www.w3.org/2001/XMLSchema#string

I Rizzello

http://www.w3.org/2001/XMLSchema#string

L Pantani

http://www.w3.org/2001/XMLSchema#string

P Tacchetti

http://www.w3.org/2001/XMLSchema#string

S Rocchi

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.

P304

315-323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474086.2016.1127754

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26634945

http://www.w3.org/2001/XMLSchema#string

Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.

about

P2860

P2860

Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698